{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:37Z","timestamp":1794047497837,"version":"4.8.0"},"reference-count":16,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2025.287681","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:08:28Z","timestamp":1744859308000},"page":"2525-2529","source":"Crossref","is-referenced-by-count":1,"title":["A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in &lt;i&gt;FLT3&lt;\/i&gt; internal tandem duplication mutation-positive (&lt;i&gt;FLT3&lt;\/i&gt;&lt;sup&gt;-&lt;\/sup&gt;ITD&lt;sup&gt;+&lt;\/sup&gt;) acute myeloid leukemia: the PONALLO trial"],"prefix":"10.3324","volume":"110","author":[{"given":"Patrice","family":"Chevallier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thiebaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussiere-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"80681","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"80682","doi-asserted-by":"crossref","unstructured":"Burchert A, Bug G, Fritz LV. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020; 38(26):2993-3002.","DOI":"10.1200\/JCO.19.03345"},{"key":"80683","doi-asserted-by":"crossref","unstructured":"Xuan L, Wang Y, Yang K. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023; 10(8):e600-e611.","DOI":"10.1016\/S2352-3026(23)00117-5"},{"key":"80684","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, Bug G, Baron F. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020; 105(6):1507-1516.","DOI":"10.3324\/haematol.2019.243410"},{"key":"80685","doi-asserted-by":"crossref","unstructured":"Morin S, Giannotti F, Mamez AC. Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption. Front Oncol. 2023; 13:1095870.","DOI":"10.3389\/fonc.2023.1095870"},{"key":"80686","doi-asserted-by":"crossref","unstructured":"Maziarz RT, Levis M, Patnaik MM. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transpl. 2021; 56(5):1180-1189.","DOI":"10.1038\/s41409-020-01153-1"},{"key":"80687","doi-asserted-by":"crossref","unstructured":"Levis MJ, Hamadani M, Logan B. BMT-CTN 1506\/MORPHO Study Investigators. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024; 42(15):1766-1775.","DOI":"10.1200\/JCO.23.02474"},{"key":"80688","doi-asserted-by":"crossref","unstructured":"Gao Y, Ding Y, Tai XR, Zhang C, Wang D. Ponatinib: an update on its drug targets, therapeutic potential and safety. Biochim Biophys Acta Rev Cancer. 2023; 1878(5):188949.","DOI":"10.1016\/j.bbcan.2023.188949"},{"key":"80689","doi-asserted-by":"crossref","unstructured":"Shah NP, Talpaz M, Deininger MW. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol. 2013; 162(4):548-552.","DOI":"10.1111\/bjh.12382"},{"key":"80690","doi-asserted-by":"crossref","unstructured":"Jentzsch M, Bischof L, Brauer D. Clinical implications of the FLT3-ITD allelic ratio in acute myeloid leukemia in the context of an allogeneic stem cell transplantation. Cancers (Basel). 2023; 15(4):1312.","DOI":"10.3390\/cancers15041312"},{"key":"80691","doi-asserted-by":"crossref","unstructured":"How J, Sykes J, Gupta V. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer. 2012; 118(24):6110-6117.","DOI":"10.1002\/cncr.27683"},{"key":"80692","doi-asserted-by":"crossref","unstructured":"Stone RM, Mandrekar SJ, Sanford BL. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464.","DOI":"10.1056\/NEJMoa1614359"},{"key":"80693","doi-asserted-by":"crossref","unstructured":"Erba HP, Montesinos P, Kim HJ. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10388):1571-1583.","DOI":"10.1016\/S0140-6736(23)00464-6"},{"key":"80694","doi-asserted-by":"crossref","unstructured":"Perl AE, Martinelli G, Cortes JE. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019; 381(18):1728-1740.","DOI":"10.1056\/NEJMoa1902688"},{"key":"80695","doi-asserted-by":"crossref","unstructured":"Lang TJL, Damm F, Bullinger L, Frick M. Mechanisms of resistance to small molecules in acute myeloid leukemia. Cancers (Basel). 2023; 15(18):4573.","DOI":"10.3390\/cancers15184573"},{"key":"80696","doi-asserted-by":"crossref","unstructured":"Mathew NR, Baumgartner F, Braun L. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018; 24(3):282-291.","DOI":"10.1038\/nm.4484"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12030\/78291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12030\/78894","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12030\/78291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:35Z","timestamp":1794046115000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.287681","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}